Contrasting increased levels of serum amyloid A in patients with three different bone sarcomas: An indicator of tumor malignancy?. Issue 17 (9th May 2016)

• Record Type: Journal Article
• Authors: Wan‐Ibrahim, Wan Izlina; Ashrafzadeh, Ali; Singh, Vivek Ajit; Hashim, Onn Haji; Abdul‐Rahman, Puteri Shafinaz
• Other Names: Guttman Andras guestEditor.
• Is Part Of: Electrophoresis. Volume 37:Issue 17/18(2016)
• Page Start: 2328
• Page End: 2337
• Publication Date: 2016-05-09
• Subjects: Chondrosarcoma -- Osteosarcoma -- Pleomorphic sarcoma -- Proteomics -- Serum amyloid A; Electrophoresis -- Periodicals; Electrophoresis -- Periodicals; 541.372
• DOI: 10.1002/elps.201500522
• Languages: English
• ISSNs: 0173-0835

Abstract

Abstract : Sarcoma is a malignant tumor that originates from the bone or soft tissue. In this study, abundances of serum amyloid A (SAA) in patients with pleomorphic sarcoma (PS), chondrosarcoma (CS), and osteosarcoma (OS) were analyzed and compared with those from their respective age‐matched healthy control subjects. Results obtained from our analysis by 2DE showed that the levels of SAA were markedly elevated in patients with PS and OS, which are highly metastatic, while in patients with CS, which is a less aggressive sarcoma, the increase appeared less pronounced. A similar trend of altered abundances was also observed when the levels of SAA in the subjects were estimated using Western blot, ELISA, and multiple‐reaction monitoring analyses. Absolute quantification using multiple‐reaction monitoring further demonstrated that the increased abundance of SAA in patients with PS, OS, and CS was mainly attributed to isoform SAA1. In view of the different degrees of tumor malignancy in PS, OS, and CS, our data suggest their apparent correlation with the levels of SAA in the patients.